1. Kristoffersen ES and Lundqvist C. Medication-overuse headache: A review. J Pain Res 2014; 7: 367–378.
  2. Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., ... & Coggeshall, M. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet, 388(10053), 1545-1602.
  3. International Classification of Headache Disorders. Cephalalgia, 38(1), 1-211
  4. Bigal, M. E., Serrano, D., Buse, D., Scher, A., Stewart, W. Bigal, M. E., Serrano, D., Buse, D., Scher, A., Stewart, W. F., & Lipton, R. B. (2008). Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population‐based study. Headache: The Journal of Head and Face Pain, 48(8), 1157-1168.
  5. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre—Clinical characteristics and treatment outcomes. Cephalalgia. 2004; 24: 483-490. doi: 10.1111/j.1468-2982.2004.00691.x.
  6. Von Korff M, Galer BS, Stang P. Chronic use of symptomatic headache medications. Pain. 1995;62(2):179-186.
  7. Tepper J, Tepper DE. Breaking the cycle of medication overuse headache. Cleveland Clin J Med. 2010; 77(4): 236 -242. doi:10.3949/ccjm.77a.09147.
  8. Edvinsson, L., & Warfvinge, K. (2017). Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia, 0333102417736900.
  9. Xie, J. Y., De Felice, M., Kopruszinski, C. M., Eyde, N., LaVigne, J., Remeniuk, B., ... & King, T. (2017). Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. Cephalalgia, 37(8), 780-794.
  10. Franklin GM. Opioids for chronic noncancer pain. Neuro. 2014; 83(14): 1277-1284. doi:10.1212 /WNL.0000000000000839.
  11. Supornsilpchai, W., le Grand, S. M., & Srikiatkhachorn, A. (2010). Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia, 30(9), 1101-1109.
  12. De Felice, M., Ossipov, M. H., Wang, R., Dussor, G., Lai, J., Meng, I. D., ... & Dodick, D. (2010). Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain, 133(8), 2475-2488.
  13. Kopruszinski, C. M., Xie, J. Y., Eyde, N. M., Remeniuk, B., Walter, S., Stratton, J., ... & Porreca, F. (2017). Prevention of stress-or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia, 37(6), 560-570.
  14. Starling, A. J., Hoffman-Snyder, C., Halker, R. B., Wellik, K. E., Vargas, B. B., Dodick, D. W., ... & Wingerchuk, D. M. (2011). Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. The neurologist, 17(5), 297-299.
  15. Kroenke K, Spitzer RL, Williams JB. An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics. 2009; 50(6): 613-621. doi: 10.1176/appi.psy.50.6.613. 
  16. Cohen, S., Kamarck, T., & Mermelstein, R. (1994). Perceived stress scale. Measuring stress: A guide for health and social scientists, 235-283.
  17. Bigal ME, Marcelo E, Lipton RB. Modifiable risk factors for migraine progression. Headache: J Head Face Pain. 2006; 46(9): 1334-1343. doi: 10.1111/j.1526-4610.2006.00577.x.
  18. Dodick DW. Diagnosing headache: clinical clues and clinical rules. Adv Stud Med. 2003; 3(2): 87-92.
  19. Young WB, Siow HC. Should butalbital-containing analgesics be banned? Yes. Curr Pain Headache Rep. 2002: 6(2); 151-155. Accessed January 8, 2018.
  20. Loder E, Weizenbaum E, Frishberg B, Silberstein S. Choosing wisely in headache medicine: The american headache society’s list of five things physicians and patients should question. Headache: J Head Face Pain. 2013: 53(10); 1651-1659. doi: 10.1111/head.12233.
  21. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003; 106: 81-89. doi: 10.1016/S0304-3959(03)00293-8.
  22. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000; 47: 614-624. 
  23. Marics, B., Peitl, B., Varga, A., Pázmándi, K., Bácsi, A., Németh, J., ... & Dux, M. (2017). Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses. Cephalalgia, 37(6), 581-591.
  24. Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med. 1992; 327: 1109-1114. doi: 10.1056/NEJM199210153271601. 
  25. Griffiths RR, Evans SM, Heishman SJ, et al. Lowdose caffeine physical dependence in humans. J Pharmacol Exp Ther. 1990; 255: 1123-1132. Accessed January 10, 2018.
  26. Scher AI, Lipton RB, Stewart WF. Habitual snoring as a risk factor for chronic daily headache. Neurology. 2003; 60: 1366-1368. doi: 10.1212/01.WNL.0000055873.71552.51.
  27. Modgill, G., Jette, N., Wang, J. L., Becker, W. J., & Patten, S. B. (2012). A population‐based longitudinal community study of major depression and migraine. Headache: The Journal of Head and Face Pain, 52(3), 422-432.
  28. Santos, I. S., Brunoni, A. R., Goulart, A. C., Griep, R. H., Lotufo, P. A., & Benseñor, I. M. (2014). Negative life events and migraine: a cross-sectional analysis of the Brazilian longitudinal study of adult health (ELSA-Brasil) baseline data. BMC public health, 14(1), 678.
  29. Krøll, L. S., Hammarlund, C. S., Westergaard, M. L., Nielsen, T., Sloth, L. B., Jensen, R. H., & Gard, G. (2017). Level of physical activity, well-being, stress and self-rated health in persons with migraine and co-existing tension-type headache and neck pain. The journal of headache and pain, 18(1), 46.
  30. Burstein, R., Noseda, R., & Borsook, D. (2015). Migraine: multiple processes, complex pathophysiology. Journal of Neuroscience, 35(17), 6619-6629.
  31. Deen M. Low 5-HTIB receptor binding in the migraine brain: A PET study. Cephalalgia. 2017; 0(0): 1-9. doi: 10.1177/0333102417698708.
  32. Medication overuse treatment strategy trial (MOTS). Accessed January 1, 2017.
  33. Schoenen, J., Vandersmissen, B., Jeangette, S., Herroelen, L., Vandenheede, M., Gérard, P., & Magis, D. (2013). Migraine prevention with a supraorbital transcutaneous stimulator A randomized controlled trial. Neurology, 80(8), 697-704.
  34. Schoenen, J. E. (2016). Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology, 86(2), 201-202.
  35. Tassorelli, C., Grazzi, L., de Tommaso, M., Pierangeli, G., Martelletti, P., Rainero, I., ... & Liebler, E. (2018). Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology, 10-1212.
  36. Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., Pearlman, S. H., ... & Goadsby, P. J. (2010). Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. The Lancet Neurology, 9(4), 373-380.
  37. Da Silva, A. N., & Lake III, A. E. (2014). Clinical aspects of medication overuse headaches. Headache: The Journal of Head and Face Pain, 54(1), 211-217.
  38. Plog, B. A., & Nedergaard, M. (2018). The glymphatic system in central nervous system health and disease: past, present, and future. Annual Review of Pathology: Mechanisms of Disease, 13, 379-394.
  39. Schain, A., Strassman, A., Melo-Carrillo, A., & Burstein, R. (2017). Cortical spreading depression closes the paravascular space and impairs glymphatic flow: Implications for migraine headache.(S47. 001). Neurology, 88(16 Supplement), S47-001.
  40. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: A clinical practice guideline from the american college of physicians. Ann Int Med. 2016; 165(2): 125-133. doi: 10.7326/M15-2175.
  41. Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized control trial. JAMA. 2001; 11(14): 1856-1864. doi: 10.1001/jama.285.14.1856.
  42. Tepper SJ. Nutraceutical and Other Modalities for the Treatment of Headache. Neurology Continuum (Minneap Minn) 2015;21:1018–1031
  43. Facchinetti F, Sances G, Borella P et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991; 31(5): 298-301. doi: 10.1111/j.1526-4610.1991.hed3105298.x. 
  44. Peres, M. F. P., Zukerman, E., da Cunha Tanuri, F., Moreira, F. R., & Cipolla-Neto, J. (2004). Melatonin, 3 mg, is effective for migraine prevention. Neurology, 63(4), 757-757.
  45. Lampl C, Haider B, Schweiger C. Long-term efficacy of Boswellia serrata in four patients with chronic cluster headache. Cephalalgia. 2012; 719(22). doi: 10.1186/1129-2377-14-S1-P37.
  46. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double blind, multicenter, placebo-controlled study. Cephalalgia. 2005. 2005; 25(11): 1031-41. 
  47. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988; 2(8604): 189-192
  48. S-Adenosyl-L-Methionine (SAMe): In depth. National Center for Complementary and Integrative Medicine.
  49. Tyrer AE, Levitan RD, Houle S, Wilosn AA, Nobrega JN, Rusjan PM, Meyer JH. Serotonin transporter binding is reduced in seasonal affective disorder following light therapy. Acta Psychiatr Scand. 2016; 134: 410-419. doi: 10.1111/acps.12632.
  50. Williams C. The fire inside. New Scientist. 2017.
  51. Junker Y, Zeissig S, Kim S et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med. 2012; 209(13): 2395-2408. doi: 10.1084/jem.20102660.
  52. Borkum, J. M. (2016). Migraine triggers and oxidative stress: a narrative review and synthesis. Headache: The Journal of Head and Face Pain, 56(1), 12-35.
  53. Varkey E, Hagen K, Zwart JA, Linde M. Physical activity and headache: results from the nord-trondelag health study (HUNT). Cephalalgia. 2008; 28(12): 1292-1297. doi: 10.1111/j.1468-2982.2008.01678.x.
  54. Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011; 31(14): 1428-1438. doi: 10.1177/0333102411419681
  55. Coughlin AM, Badura AS, Fleischer TD, Guck TP. Multidisciplinary treatment of chronic pain patients: its efficacy in changing patient locus of control. Arch Phys Med Rehabil. 2000; 81(6): 739-740. doi: 10.1053/apmr.2000.5586.
  56. Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback. 2008; 33: 125-40. doi:10.1007/s10484- 008-9060-3.
University of Washington logo
University of Washington